CD274 and cholangiocarcinoma: Inhibiting this pathway has shown promise in other cancers (91), and combination therapies targeting both PD-1/PD-L1 and metabolic pathways (e.g., lactate dehydrogenase [LDH] inhibitors or metabolic reprogramming agents) are being investigated to improve treatment efficacy in CCA (34, 92).